SCHEMBL2912907

SCHEMBL2912907

Cc1ccc(C(=O)O)cc1-c1ccc(NC(=O)Cc2cccc(Cl)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 2/20 0.57
KDM4E B2RXH2 2/20 0.54
KCNQ2 O43526 3/20 0.51
ADRB1 P08588 2/20 0.49
ADRB3 P13945 2/20 0.49
ADRB2 P07550 1/20 0.49
RORC P51449 2/20 0.47
SUCNR1 Q9BXA5 1/20 0.47
TP53 P04637 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
PLK4 O00444 1/20 0.44
AURKA O14965 1/20 0.44
DYRK3 O43781 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909884 0.81 HDAC1 (0.57) ALDH1A1ADRB1ADRB3ADRB2SUCNR1
SCHEMBL2350840 0.81 KCNQ2 (0.60) ALDH1A1KDM4EKCNQ2NPC1RAB9A
SCHEMBL2912073 0.77 HDAC1 (0.55) ALDH1A1ADRB1ADRB3ADRB2SMN1; SMN2
SCHEMBL13752569 0.76 MEN1 (0.57) MEN1KMT2AALDH1A1KDM4EKCNQ2
SCHEMBL2744942 0.76 ADRB1 (0.56) ADRB1ADRB3ADRB2NPC1RAB9A
SCHEMBL2913517 0.74 KMT2A (0.59) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL3120014 0.74 MEN1 (0.54) MEN1KMT2AALDH1A1KDM4EKCNQ2
SCHEMBL2183597 0.73 PSEN1 (0.79) MEN1KMT2AALDH1A1RORCPSEN1
SCHEMBL15650665 0.73 MEN1 (0.74) MEN1KMT2AALDH1A1KDM4EKCNQ2
SCHEMBL13544615 0.71 EPHX2 (0.69) MEN1KMT2AALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 MEN1 3163/4885KMT2A 3804/4885ALDH1A1 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.